2013 revenue: $44.033 billion
2012 revenue: $47.267 billion
Merck ($MRK) knew its sales picture last year wouldn't be as pretty as it once was, what with former top-seller Singulair now under siege from copycat drugs. The generic attack on Singulair pulled pharma sales for Merck down 8% to $44 billion, once adjusted for foreign currency issues; full-year global sales of the drug slid 69% to $1.2 billion, continuing the trend that has so far forced a $2.5 billion global restructuring and thousands of layoffs.
But Merck had a couple of bright spots on the pharma side, including Remicade and Simponi, which treat inflammatory diseases. Together, they grew 19% and 15% for the year; on its own, sales of Simponi ballooned 51% for the year to hit $500 million. Respiratory drug Dulera, too, made big gains, stealing market share from GlaxoSmithKline ($GSK) behemoth Advair. It posted a 56% gain for the year, generating $324 million in sales.
On the vaccines side, sales of HPV vax Gardasil swelled 12% in 2013 to reach $1.8 billion, up from $1.6 billion in 2012. Zostavax, for shingles, made strides as well, with revenues picking up by 16% to tally $758 million.
Other units didn't see the same growth, with animal health sinking 1% and a Claritin OTC drop of 12% dragging down the consumer care division. The company is currently evaluating both units to decide their fate; the consumer business in particular has reportedly drawn interest from other pharma giants eager to bolster their own offerings, including Bayer and Novartis ($NVS).
-- Carly Helfand (email | Twitter)
Special Reports: Top 10 Drug Patent Losses of 2014 - Nasonex, Merck | Top Pharma Companies by 2012 Revenues - Merck
Analysts cheer on Merck's comeback campaign, pumping up blockbuster forecasts
Merck's earnings miss slightly but it was not the 'mega-miss' some anticipated
Merck CEO: We'll decide fate of animal health, consumer biz by year's end
Merck sales slump again, but cost cuts keep earnings coming